A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

@article{Kelly2013API,
  title={A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.},
  author={Ronan Joseph Kelly and Alexandra Thomas and Arun Tejusve Raghunath Rajan and Guinevere Chun and Ariel Lopez-Chavez and Eva Szabo and Sandra Spencer and Corey Allan Carter and Udayan Guha and Sean Khozin and Srinivasu Poondru and Chip Van Sant and Ashley Keating and Seth Steinberg and William D. Figg and Guiseppe Giaccone},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 10},
  pages={2601-6}
}
BACKGROUND This phase I/II study examined the safety and efficacy of Sepantronium Bromide (S), a small-molecule selective survivin suppressant, administered in combination with carboplatin (C) and paclitaxel (P). PATIENTS AND METHODS Forty-one patients were treated on study. Twenty-two patients received escalating doses of S (3.6-12 mg/m(2)) and 19 with… CONTINUE READING